SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (123)10/10/1997 6:59:00 PM
From: tdinovo   of 496
 
Neuro,
I see your point. But it may be a matter of having pre-clinicals in good shape for GPI-1046 versus the incremental time to get GPI-1234 to the same state. Besides, I think half Amgen's staff are patent attorneys. I don't know if you followed the fisticuffs with Genetic Institue when EPO first hit the market. I don't think Amgen is afarid of a patent fight and they have the ultimate hammer in GPI-1234. In any event, those statements are simply what the JP people reported and they were breaking bread with GLFD management. So, who knows?

Ted
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News